Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Biocept launched its c-MET amplification detection test. This diagnostic assay, which uses a blood-based liquid biopsy, has the potential to help physicians identify patients who may be receptive to certain gastric and non-small cell lung cancer treatments.
Biocartis and Fast-track Diagnostics have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla system. The two companies plan to collaborate on a new approach to infectious disease diagnostics, “syndromic multiplex testing,” which enables the identification of a broad range of disease pathogens in a single test.
Qiagen announced a collaboration with Seegene in which Seegene will develop a menu of multiplex assay panels for Qiagen’s modular QIAsymphony RGQ MDx automation platform.
DiaSorin and Beckman Coulter Diagnostics have signed a distribution partnership agreement for the commercialization in China of DiaSorin Hepatitis B, C, and HIV tests on DiaSorin’s Liaison XL LAS connected to Beckman Coulter’s Power Express and Power Processor automated sample processing systems.
CLSI’s Excellence Awards are bestowed on volunteers who are dedicated and committed to the organization’s mission and who significantly contribute their services to the development, implementation, and promotion of consensus standards. The winners were nominated by their peers and then selected by the CLSI Awards Committee and announced in July.
Biomedical Polymers has received ISO 13485:2003 certification for its Quality Management System for the manufacture of Medical Devices. In order to meet these requirements for certification, BMP upgraded its quality management system to assist in achieving increased efficiencies, higher performance, and reduced operational costs.
Ariosa Diagnostics’ proprietary Forte software received the CE mark—a significant achievement toward the continued expansion of the Harmony Prenatal Test in Europe and worldwide, according to a company statement.
SeraCare Life Sciences’ new precision medicine business unit has launched its first product, the Seraseq Solid Tumor Mutation Mix—I (AF20), a biosynthetic reference material designed to evaluate the performance of next-generation-sequencing–based tumor profiling assays.
Medtronic offers the GenCut core biopsy system, a lung tissue biopsy tool for use with the SuperDimension navigation system, which enables a minimally invasive approach to accessing difficult-to-reach areas of the lung.
Sarstedt introduced its next generation of cell culture flasks, dishes, and plates redesigned for “superior growth, economic handling, and traceability,” according to a company statement. All items are imprinted with lot number and expiration date and are individually color-coded for one of three culture surfaces. Flasks and dishes are packaged in resealable zip bags, and individual plate packaging has been optimized for easy opening and compact storage.
